These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 1396349

  • 1. A patient with a prolactinoma associated with an aldosterone producing adrenal adenoma: differences in dopaminergic regulation of PRL and aldosterone secretion.
    Demura R, Naruse M, Isawa M, Onoda N, Naruse K, Yamakado M, Demura H.
    Endocrinol Jpn; 1992 Apr; 39(2):169-76. PubMed ID: 1396349
    [Abstract] [Full Text] [Related]

  • 2. Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
    Zacharieva S, Stoeva I, Andreeva M, Kalinov K, Matrozov P, Andonova K.
    Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):593-7. PubMed ID: 9010834
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Plasma aldosterone response to metoclopramide is unmodified by hyperprolactinemia.
    Serri O.
    Horm Res; 1987 Nov; 27(1):36-41. PubMed ID: 3623428
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
    De Leo V, Petraglia F, Sardelli S, Danero S, Genazzani AR, D'Antona N.
    Obstet Gynecol; 1987 Jan; 69(1):99-103. PubMed ID: 3099236
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S, Tsiganou E, Tzavara I, Nikolou H, Thalassinos N.
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
    [Abstract] [Full Text] [Related]

  • 9. Effects of bromocriptine on renin, aldosterone, and prolactin responses to posture and metoclopramide in idiopathic edema: possible therapeutic approach.
    Sowers J, Catania R, Paris J, Tuck M.
    J Clin Endocrinol Metab; 1982 Mar; 54(3):510-6. PubMed ID: 7035482
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.
    Carey RM, Thorner MO, Ortt EM.
    J Clin Invest; 1980 Jul; 66(1):10-8. PubMed ID: 7400305
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of metergoline on the aldosterone-stimulating properties of metoclopramide.
    Opocher G, Murgia A, Boscaro M, D'Agostino D, Fallo F, Mantero F.
    J Steroid Biochem; 1983 Jul; 19(1B):531-6. PubMed ID: 6350721
    [Abstract] [Full Text] [Related]

  • 14. Evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinoma.
    Jungmann E, Schwedes U, Althoff PH, Rosak C, Schöffling K.
    Horm Metab Res; 1986 Oct; 18(10):704-5. PubMed ID: 3781476
    [Abstract] [Full Text] [Related]

  • 15. Evidence for dopamine-related and TRH-related pituitary TSH and PRL pools in patients with prolactinoma.
    Hanew K, Utsumi A, Sugawara A, Shimizu Y, Yoshinaga K.
    Acta Endocrinol (Copenh); 1991 May; 124(5):545-52. PubMed ID: 1903012
    [Abstract] [Full Text] [Related]

  • 16. Zona fasciculata-like cells determine the response of plasma aldosterone to metoclopramide and aldosterone synthase messenger ribonucleic acid level in aldosterone-producing adenoma.
    Wu KD, Chen YM, Chu JS, Hung KY, Hsieh TS, Hsieh BS.
    J Clin Endocrinol Metab; 1995 Mar; 80(3):783-9. PubMed ID: 7883831
    [Abstract] [Full Text] [Related]

  • 17. Resistance to bromocriptine in prolactinomas.
    Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A.
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [Abstract] [Full Text] [Related]

  • 18. Prolactin secretion in the empty sella syndrome, in prolactinomas and in acromegaly.
    Brismar K.
    Acta Med Scand; 1981 Sep; 209(5):397-405. PubMed ID: 6787839
    [Abstract] [Full Text] [Related]

  • 19. Mineralocorticoid and prolactin response to the dopamine antagonist metoclopramide in patients with primary aldosteronism.
    Witzgall H, von Werder K, Weber PC.
    J Steroid Biochem; 1983 Nov; 19(5):1671-6. PubMed ID: 6645503
    [Abstract] [Full Text] [Related]

  • 20. Dopaminergic modulation of aldosterone secretions on changes of sodium intake in aldosterone-producing adenoma.
    Wu KD, Chen YM, Chu TS, Chueh SC, Tsai GC, Tseng YZ, Hsieh BS.
    Am J Hypertens; 2002 Jul; 15(7 Pt 1):609-14. PubMed ID: 12118908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.